Hill A - Search Results

1

Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A. Arshad U, et al. Among authors: hill a. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. Clin Pharmacol Ther. 2020. PMID: 32438446 Free PMC article. Review.

2

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A. Boffito M, et al. Among authors: hill a. Br J Clin Pharmacol. 2005 Jan;59(1):38-42. doi: 10.1111/j.1365-2125.2004.02240.x. Br J Clin Pharmacol. 2005. PMID: 15606438 Free PMC article.

3

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Ford J, et al. Among authors: hill a. J Antimicrob Chemother. 2006 Nov;58(5):1009-16. doi: 10.1093/jac/dkl379. Epub 2006 Sep 19. J Antimicrob Chemother. 2006. PMID: 16984898

4

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

Jackson A, Hill A, Puls R, Else L, Amin J, Back D, Lin E, Khoo S, Emery S, Morley R, Gazzard B, Boffito M. Jackson A, et al. Among authors: hill a. J Antimicrob Chemother. 2011 Mar;66(3):635-40. doi: 10.1093/jac/dkq468. Epub 2010 Dec 17. J Antimicrob Chemother. 2011. PMID: 21172791 Free PMC article.

5

Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?

Hill A, Khoo S, Boffito M, Back D. Hill A, et al. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):e137-8. doi: 10.1097/QAI.0b013e318237ccae. J Acquir Immune Defic Syndr. 2011. PMID: 22075603 No abstract available.

6

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.

Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M. Else LJ, et al. Among authors: hill a. Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19. Antimicrob Agents Chemother. 2012. PMID: 22183172 Free PMC article. Clinical Trial.

7

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Hill A, et al. Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6. Clin Infect Dis. 2014. PMID: 24399087 Free PMC article.

8

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

Hill A, Khoo S, Back D, Pozniak A, Boffito M. Hill A, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19583. doi: 10.7448/IAS.17.4.19583. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394089 Free PMC article.

9

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R; ENCORE1 Study Group. Dickinson L, et al. Clin Pharmacol Ther. 2015 Oct;98(4):406-16. doi: 10.1002/cpt.156. Epub 2015 Jul 14. Clin Pharmacol Ther. 2015. PMID: 26044067 Free PMC article. Clinical Trial.

10

Estimated generic prices for novel treatments for drug-resistant tuberculosis.

Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE 3rd, Hill A. Gotham D, et al. Among authors: hill a. J Antimicrob Chemother. 2017 Apr 1;72(4):1243-1252. doi: 10.1093/jac/dkw522. J Antimicrob Chemother. 2017. PMID: 28073970 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,573 results

Search Page

Filters